Teladoc price target lowered to $27 from $30 at Credit Suisse

Credit Suisse analyst Jonathan Yong lowered the firm’s price target on Teladoc to $27 from $30 and keeps a Neutral rating on the shares following the Q4 results. The key for the stock will ultimately come down to driving top-line growth while maintaining profitability without the use of cost cuts, particularly as A&M is a key swing factor for the BetterHelp business, the analyst tells investors in a research note. There likely remain concerns in the near-term on the company’s growth prospects while enhancing EBITDA without cost reductions, the firm adds.